ADARx Pharmaceuticals Eyes $1.74 Billion IPO for RNA Therapy Funding

By EC Assets · Published 21 September 2026

ADARx Pharmaceuticals is seeking a $1.74 billion valuation in its upcoming U.S. initial public offering. The clinical-stage biotechnology company filed for the IPO to secure funding for its RNA therapy pipeline. The offering aims to support ongoing clinical trials for a range of next-generation small interfering RNA (siRNA) medicines. The company is developing next-generation RNA therapeutics. Its IPO seeks to fund this RNA therapy pipeline. ADARx Pharmaceuticals is backed by AbbVie. The company plans its IPO to bankroll array of clinical-stage siRNA therapies. ADARx Pharmaceuticals announced the appointment of Dr. Chris Storgard as Chief Medical Officer on April 2, 2024. More recently, on February 5, 2026, the company announced the appointment of Donald Fong, M.D. as Chief Medical Officer. The collaboration leverages AbbVie's expertise in biotherapeutic drug development and commercialization. It also uses ADARx's proprietary RNA technology. This partnership aims to advance next-generation siRNA therapies across multiple therapeutic areas. This article is intended for informational purposes only. It does not constitute investment advice.